항체약물접합체(ADC) 시장 : 암별, 페이로드별, 표적별, 제품별, 사용자별, 국가/지역별 시장 예측 - 이그제큐티브 가이드 및 컨설턴트 가이드(2026-2030년)

Antibody Drug Conjugates Markets. ADC Market Forecasts by cancer, by payload, by target, by product, by user and by country/region including Executive and Consultant Guides. 2026 to 2030

US $ 6,995 ￦ 10,360,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 15,545,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 20,729,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 개요:

최신 보고서를 통해 이 시장을 파악해 보세요. 기회를 쫓는 100개 기업을 분석하고, 각 기업의 계획을 설명합니다. 상세한 상황분석을 통해 몇 페이지로 전체상을 정리합니다.

암, 페이로드, 타겟, 제품, 사용자, 국가 등 다양한 각도에서 시장을 분석합니다. 이 시장 기회를 이해하실 수 있습니다.

이미 수 십억 달러 규모 세계 시장은 극적인 성장을 앞두고 있습니다. 의료산업에 미치는 영향은 헤아릴 수 없을 정도로 큽니다. 이 보고서에서는 향후 5년간 시장 규모를 예측했습니다.

기회와 함정을 파악하고, 성장 예측과 궁극적인 시장 규모의 잠재력을 이해할 수 있습니다.

모든 보고서 데이터는 요청에 따라 엑셀 형식으로 제공 가능합니다.

최신 데이터와 종합적인 분석을 활용하여 자신감 있는 의사결정을 내릴 수 있습니다.

목차

제1장 시장 가이드

제2장 도입과 시장 정의

• 항체약물접합체란 무엇인가
• 면역치료 - 다가오는 치료법
• 시장 정의
• 조사 방법
• 미국의 의료 시장과 의약품 지출 - 전망

제3장 항체약물접합체

• 면역 시스템
  • 선천성 면역 시스템
  • 적응 면역 시스템
  • 종양 면역학 - 면역 모니터링 시스템
• ADC 기술

제4장 업계 개요

• 시장 참여 기업 - 역할과 영향
  • 의약품 제조업체 - 대형/제약
  • 의약품 제조업체 - 제네릭 의약품
  • 연구개발 수탁 기관 및 제조 수탁 기관
  • 체외진단 업계
  • 의약품 마케팅 회사
  • 바이오테크놀러지 기업
  • 규제기관

제5장 시장 동향

• 성장 촉진요인
  • 결과의 가능성
  • 패스트 트래킹
  • 자금조달
  • 기술 환경
  • 타겟 솔루션
• 성장 억제요인
  • 치료비
  • 임상시험의 역할
  • 조합
  • 프로토콜
• 치료 기술개발
  • 조합 ― 문제와 복잡성
  • 약의 선호도
  • 면역 공학의 문제점
  • 비용의 역할
  • 파괴 역학
• 2024년 항체약물접합체(ADC)의 세계 판매량

제6장 ADC 최근 동향

• 최근 동향 - 이 섹션의 중요성과 사용 방법
• Merck, ADC 요법의 개발에 7억 달러를 확보
• Enhertu가 Roche의 Kadcyla를 제친다.
• Innovent가 Takeda와 114억 달러의 암 치료 계약을 체결
• Tubuli이 표적 암 치료제 개발을 위해 3억 5,800만 달러를 조달
• Roche가 폐암 ADC로 8000만 달러 계약을 체결
• Trodelvy와 Keytruda 병용이 제3상시험에서 성공
• GSK가 전립선암 ADC 권리를 취득
• Samsung Bioepis와 Phrontline가 ADC 개발로 제휴
• Phrontline Biopharma, 이중특이성 및 듀얼 페이로드 ADC용으로 6,000만 달러를 조달
• Kelun가 ADC-Keytruda 조합으로 제3상 돌파
• Datopotamab deruxtecan 생물제제 라이선스 신청이 수리된다.
• FDA, Daiichi와 AstraZeneca 고형 종양 치료제를 승인
• AstraZeneca, 15억 달러 규모의 ADC 공장을 건설
• Samsung Biologics가 ADC 제조·서비스 사업을 확대
• Ipsen과 Foreseen Biotechnology가 ADC 라이선싱 계약을 발표
• PDC vs. ADC : 새로운 경지
• MilliporeSigma, ADC 제조용 일회용 리액터를 발매
• Ono가 신규 ADC 후보 물질을 창출
• Gilead와 Tubulis가 고형암용 ADC 후보를 개발

제7장 주요 ADC 기업의 개요

• ADC Therapeutics
• AbbVie
• Abzena
• Adcendo
• Adcentrx Therapeutics
• Adcytherix
• Alentis Therapeutics
• Alphamab Oncology
• Alteogen
• Ambrx
• Amgen
• Antengene
• Astellas Pharma
• Axcynsis Therapeutics
• Axplora
• BeiGene
• BeOne Medicines
• BioAtla
• Bio-Thera Solutions
• Biotheus
• BiVictriX Therapeutics
• BioNTech
• Bicycle Therapeutics
• Bolt Biotherapeutics
• Bright Peak Therapeutics
• Bristol Myers Squibb(BMS)
• Byondis
• Callio Therapeutics
• Catalent Biologics
• CSPC Pharmaceutical Group
• CytomX Therapeutics
• Daiichi Sankyo
• Debiopharm
• Duality Biologics
• Eisai
• Eli Lilly
• Exelixis
• Fosun Pharma
• Genentech(Roche)
• Genmab
• GenScript Biotech
• Gilead Sciences
• GlaxoSmithKline(GSK)
• Hansoh Pharma
• Hengrui Pharma
• Heidelberg Pharma
• Iksuda Therapeutics
• ImmunoGen
• Innate Pharma
• Innovent Biologics
• iProgen Biotech
• Janssen Biotech(Johnson & Johnson)
• Kelun-Biotech
• KLUS Pharma
• LegoChem Biosciences(LegoChemBio)
• Lepu Biopharma
• Lonza Pharma & Biotech/Synaffix
• MacroGenics
• MBrace Therapeutics
• MediLink Therapeutics
• Merck & Co.(MSD)
• Merck KGaA(EMD Serono)
• Mersana Therapeutics
• Molecular Templates
• NBE Therapeutics(a subsidiary of Boehringer Ingelheim)
• Novartis
• OBI Pharma
• OmniAb
• Oncomatryx
• OnCusp Therapeutics
• Orum Therapeutics
• Oqory
• Oxford BioTherapeutics
• Pacylex Pharmaceuticals
• Pfizer
• Phrontline Biopharma
• ProfoundBio
• Promega
• Pyxis Oncology
• Radiance Biopharma
• Rakuten Aspyrian(Aspyrian Therapeutics)
• RemeGen
• Roche
• Rongchang Pharmaceuticals(RCBio)
• Sanofi
• Seagen
• Solve Therapeutics(Solve Tx)
• Sorrento Therapeutics
• Starpharma
• Sutro Biopharma
• Synaffix(a Lonza Company)
• SystImmune
• Takeda Pharmaceutical
• Tesaro/GSK Oncology
• Tubulis
• UCB
• VelosBio
• WuXi XDC
• Xencor
• Zai Lab

제8장 ADC 치료제의 세계 시장

• 국가별 세계 시장 개요
• 암별 세계 시장 - 개요
• 페이로드별 세계 시장 - 개요
• 표적별 세계 시장 - 개요
• 제품별 세계 시장 - 개요
• 사용자별 세계 시장 - 개요

제9장 세계의 ADC 시장 - 암별

• 유방암
• 혈액·림프액암
• 폐암
• 기타

제10장 ADC 치료제 시장 - 페이로드별

• Auristatin
• Maytansinoid
• Topoisomerase
• 기타

제11장 ADC 치료제 시장 - 표적별

• HER2
• CD30
• TROP2
• CD79b
• Nectin 4
• 기타

제12장 ADC 치료제 시장 - 제품별

• Enhertu
• Kadcyla
• Padcev
• Adcetris
• Trodelvy
• Polivy
• 기타

제13장 ADC 치료제 시장 - 사용자별

• 임상
• 트라이얼
• 연구
• 기타

제14장 부록

KSA

영문 목차

영문목차

Report Overview:

Get a handle on this market with our latest report. We analyze 100 Companies who are rushing after the opportunity and explain their plans. A detailed Situation Analysis sums up the big picture in a few pages.

We look at the market from every angle: Cancer, Payload, Target, Product, User and Country. Understand this market opportunity.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out for five years.

Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

All report data is available in Excel format on request.

Make decisions with confidence using the latest data and comprehensive analysis.

Table of Contents

1 Market Guides

• 1.1 Situation Analysis
• 1.2 Guide for Executives and Marketing Staff
• 1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

• 2.1 What are Antibody Drug Conjugates?
• 2.2 Immunotherapy - the looming cures
• 2.3 Market Definition
  • 2.3.1 Market Size
  • 2.3.2 Currency
  • 2.3.3 Years
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective
  • 2.5.1 Global Expenditures for Medicines

3 Antibody Drug Conjugates

• 3.1 The Immune System
  • 3.1.1 Innate immune system
    • 3.1.1.1 Surface barriers
    • 3.1.1.2 Inflammation
    • 3.1.1.3 Complement system
    • 3.1.1.4 Cellular barriers
    • 3.1.1.5 Natural killer cells
  • 3.1.2 Adaptive immune system
    • 3.1.2.1 Lymphocytes
    • 3.1.2.2 Killer T cells
    • 3.1.2.3 Helper T cells
    • 3.1.2.4 Gamma delta T cells
    • 3.1.2.5 B lymphocytes and antibodies
  • 3.1.3 Tumor immunology - the immune surveillance system
• 3.2 ADC Technology
  • 3.2.1.1 Outlook for Antibody Drug Conjugates
  • 3.2.1.2 Selected Companies with Antibody Drug Conjugates in their Pipeline

4 Industry Overview

• 4.1 Market Players - Roles & Impacts
  • 4.1.1 Drug manufacturers - Larger/pharmaceutical
  • 4.1.2 Drug manufacturers - Generic
  • 4.1.3 Contract Research and Manufacturing
  • 4.1.4 In Vitro Diagnostics Industry
  • 4.1.5 Drug Marketing Companies
  • 4.1.6 Biotechnology Companies
  • 4.1.7 Regulatory Bodies

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 Outcome potential
  • 5.1.2 Fast tracking
  • 5.1.3 Funding
  • 5.1.4 Technology Environment
  • 5.1.5 Target Solutions
• 5.2 Factors Limiting Growth
  • 5.2.1 Cost of Treatment
  • 5.2.2 Clinical Trials Role
  • 5.2.3 Combinations
  • 5.2.4 Protocols
• 5.3 Therapeutic Technology Development
  • 5.3.1 Combinations - Issues and Complexity
  • 5.3.2 Preference for a drug
  • 5.3.3 Problems of Immunity Engineering
  • 5.3.4 The Role of Cost
  • 5.3.5 The Disruption Dynamic
• 5.4 Global Sales of Antibody-drug Conjugates (ADCs) in 2024
  • 5.4.1 Enhertu Sales in 2024/2023
  • 5.4.2 Kadcyla Sales in 2024/2023
  • 5.4.3 Padcev Sales in 2024/2023
  • 5.4.4 Adcetris Sales in 2024/2023
  • 5.4.5 Trodelvy Sales in 2024/2023
  • 5.4.6 Polivy Sales in 2024/2023
  • 5.4.7 The Next Five Years

6 ADC Recent Developments

• 6.1 Recent Developments - Importance and How to Use This Section
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 Merck secures $700 million to develop ADC therapy
• 6.3 Enhertu tops Roche's Kadcyla
• 6.4 Innovent signs $11.4 billion cancer therapy deal with Takeda
• 6.5 Tubulis raises $358 million to develop targeted cancer treatments
• 6.6 Roche closes $80M deal for lung cancer ADC
• 6.7 Trodelvy and Keytruda combo succeeds in Phase 3
• 6.8 GSK acquires rights for prostate cancer ADC
• 6.9 Samsung Bioepis and Phrontline partner for ADC development
• 6.10 Phrontline Biopharma raises $60M for bispecific and dual-payload ADCs
• 6.11 Kelun has phase 3 win for ADC-Keytruda combo
• 6.12 Datopotamab deruxtecan Biologics License Application accepted
• 6.13 FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
• 6.14 AstraZeneca to build $1.5-bln ADC plant
• 6.15 Samsung Biologics expands into ADC manufacturing and services
• 6.16 Ipsen and Foreseen Biotechnology announce licensing agreement for ADC
• 6.17 PDCs vs. ADCs: A New Frontier
• 6.18 MilliporeSigma launches single-use reactor for ADC manufacturing
• 6.19 Ono to generate novel ADC candidates
• 6.20 Gilead and Tubulis to develop ADC candidate for solid tumor

7 Profiles of Key ADC Companies

• 7.1 ADC Therapeutics
• 7.2 AbbVie
• 7.3 Abzena
• 7.4 Adcendo
• 7.5 Adcentrx Therapeutics
• 7.6 Adcytherix
• 7.7 Alentis Therapeutics
• 7.8 Alphamab Oncology
• 7.9 Alteogen
• 7.10 Ambrx
• 7.11 Amgen
• 7.12 Antengene
• 7.13 Astellas Pharma
• 7.14 Axcynsis Therapeutics
• 7.15 Axplora
• 7.16 BeiGene
• 7.17 BeOne Medicines
• 7.18 BioAtla
• 7.19 Bio-Thera Solutions
• 7.20 Biotheus
• 7.21 BiVictriX Therapeutics
• 7.22 BioNTech
• 7.23 Bicycle Therapeutics
• 7.24 Bolt Biotherapeutics
• 7.25 Bright Peak Therapeutics
• 7.26 Bristol Myers Squibb (BMS)
• 7.27 Byondis
• 7.28 Callio Therapeutics
• 7.29 Catalent Biologics
• 7.30 CSPC Pharmaceutical Group
• 7.31 CytomX Therapeutics
• 7.32 Daiichi Sankyo
• 7.33 Debiopharm
• 7.34 Duality Biologics
• 7.35 Eisai
• 7.36 Eli Lilly
• 7.37 Exelixis
• 7.38 Fosun Pharma
• 7.39 Genentech (Roche)
• 7.40 Genmab
• 7.41 GenScript Biotech
• 7.42 Gilead Sciences
• 7.43 GlaxoSmithKline (GSK)
• 7.44 Hansoh Pharma
• 7.45 Hengrui Pharma
• 7.46 Heidelberg Pharma
• 7.47 Iksuda Therapeutics
• 7.48 ImmunoGen
• 7.49 Innate Pharma
• 7.50 Innovent Biologics
• 7.51 iProgen Biotech
• 7.52 Janssen Biotech (Johnson & Johnson)
• 7.53 Kelun-Biotech
• 7.54 KLUS Pharma
• 7.55 LegoChem Biosciences (LegoChemBio)
• 7.56 Lepu Biopharma
• 7.57 Lonza Pharma & Biotech / Synaffix
• 7.58 MacroGenics
• 7.59 MBrace Therapeutics
• 7.60 MediLink Therapeutics
• 7.61 Merck & Co. (MSD)
• 7.62 Merck KGaA (EMD Serono)
• 7.63 Mersana Therapeutics
• 7.64 Molecular Templates
• 7.65 NBE Therapeutics (a subsidiary of Boehringer Ingelheim)
• 7.66 Novartis
• 7.67 OBI Pharma
• 7.68 OmniAb
• 7.69 Oncomatryx
• 7.70 OnCusp Therapeutics
• 7.71 Orum Therapeutics
• 7.72 Oqory
• 7.73 Oxford BioTherapeutics
• 7.74 Pacylex Pharmaceuticals
• 7.75 Pfizer
• 7.76 Phrontline Biopharma
• 7.77 ProfoundBio
• 7.78 Promega
• 7.79 Pyxis Oncology
• 7.80 Radiance Biopharma
• 7.81 Rakuten Aspyrian (Aspyrian Therapeutics)
• 7.82 RemeGen
• 7.83 Roche
• 7.84 Rongchang Pharmaceuticals (RCBio)
• 7.85 Sanofi
• 7.86 Seagen
• 7.87 Solve Therapeutics (Solve Tx)
• 7.88 Sorrento Therapeutics
• 7.89 Starpharma
• 7.90 Sutro Biopharma
• 7.91 Synaffix (a Lonza Company)
• 7.92 SystImmune
• 7.93 Takeda Pharmaceutical
• 7.94 Tesaro / GSK Oncology
• 7.95 Tubulis
• 7.96 UCB
• 7.97 VelosBio
• 7.98 WuXi XDC
• 7.99 Xencor
• 7.100 Zai Lab

8 The Global Market for ADC Therapeutics

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by Cancer - Overview
  • 8.2.1 Table - Global Market by Cancer
  • 8.2.2 Chart - Global Market by Cancer - Base/Final Year
  • 8.2.3 Chart - Global Market by Cancer - Base Year
  • 8.2.4 Chart - Global Market by Cancer - End Year
  • 8.2.5 Chart - Global Market by Cancer - Share by Year
  • 8.2.6 Chart - Global Market by Cancer - Segments Growth
• 8.3 Global Market by Payload - Overview
  • 8.3.1 Table - Global Market by Payload
  • 8.3.2 Chart - Global Market by Payload - Base/Final Year
  • 8.3.3 Chart - Global Market by Payload - Base Year
  • 8.3.4 Chart - Global Market by Payload - End Year
  • 8.3.5 Chart - Global Market by Payload - Share by Year
  • 8.3.6 Chart - Global Market by Payload - Segments Growth
• 8.4 Global Market by Target - Overview
  • 8.4.1 Table - Global Market by Target
  • 8.4.2 Chart - Global Market by Target - Base/Final Year Comparison
  • 8.4.3 Chart - Global Market by Target - Base Year
  • 8.4.4 Chart - Global Market by Target - End Year
  • 8.4.5 Chart - Global Market by Target - Share by Year
  • 8.4.6 Chart - Global Market by Target - Segments Growth
• 8.5 Global Market by Product - Overview
  • 8.5.1 Table - Global Market by Product
  • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 8.5.3 Chart - Global Market by Product - Base Year
  • 8.5.4 Chart - Global Market by Product - End Year
  • 8.5.5 Chart - Global Market by Product - Share by Year
  • 8.5.6 Chart - Global Market by Product - Segments Growth
• 8.6 Global Market by User - Overview
  • 8.6.1 Table - Global Market by User
  • 8.6.2 Chart - Global Market by User - Base/Final Year Comparison
  • 8.6.3 Chart - Global Market by User - Base Year
  • 8.6.4 Chart - Global Market by User - End Year
  • 8.6.5 Chart - Global Market by User - Share by Year
  • 8.6.6 Chart - Global Market by User - Segments Growth

9 Global ADC Markets - By Cancer

• 9.1 Breast
  • 9.1.1 Table Breast - by Country
  • 9.1.2 Chart - Breast Growth
• 9.2 Blood/Lymph Cancer
  • 9.2.1 Table Blood Cancer - by Country
  • 9.2.2 Chart - Blood Cancer Growth
• 9.3 Lung Cancer
  • 9.3.1 Table Lung Cancer - by Country
  • 9.3.2 Chart - Lung Cancer Growth
• 9.4 Other Cancer
  • 9.4.1 Table Other Cancer - by Country
  • 9.4.2 Chart - Other Cancer Growth

10 ADC Therapeutic Markets - By Payload

• 10.1 Auristatin
  • 10.1.1 Table Auristatin - by Country
  • 10.1.2 Chart - Auristatin Growth
• 10.2 Maytansinoid
  • 10.2.1 Table Maytansinoid - by Country
  • 10.2.2 Chart - Maytansinoid Growth
• 10.3 Topoisomerase
  • 10.3.1 Table Topoisomerase - by Country
  • 10.3.2 Chart - Topoisomerase Growth
• 10.4 Other Payload
  • 10.4.1 Table Other Payload - by Country
  • 10.4.2 Chart - Other Payload Growth

11 ADC Therapeutic Markets - By Target

• 11.1 HER2
  • 11.1.1 Table HER2 - by Country
  • 11.1.2 Chart - HER2 Growth
• 11.2 CD30
  • 11.2.1 Table CD30 - by Country
  • 11.2.2 Chart - CD30 Growth
• 11.3 TROP2
  • 11.3.1 Table TROP2 - by Country
  • 11.3.2 Chart - TROP2 Growth
• 11.4 CD79b
  • 11.4.1 Table CD79b - by Country
  • 11.4.2 Chart - CD79b Growth
• 11.5 Nectin 4
  • 11.5.1 Table Nectin 4 - by Country
  • 11.5.2 Chart - Nectin 4 Growth
• 11.6 Other Target
  • 11.6.1 Table Other Target - by Country
  • 11.6.2 Chart - Other Target Growth

12 ADC Therapeutic Markets - By Product

• 12.1 Enhertu
  • 12.1.1 Table Enhertu - by Country
  • 12.1.2 Chart - Enhertu Growth
• 12.2 Kadcyla
  • 12.2.1 Table Kadcyla - by Country
  • 12.2.2 Chart - Kadcyla Growth
• 12.3 Padcev
  • 12.3.1 Table Padcev - by Country
  • 12.3.2 Chart - Padcev Growth
• 12.4 Adcetris
  • 12.4.1 Table Adcetris - by Country
  • 12.4.2 Chart - Adcetris Growth
• 12.5 Trodelvy
  • 12.5.1 Table Trodelvy - by Country
  • 12.5.2 Chart - Trodelvy Growth
• 12.6 Polivy
  • 12.6.1 Table Polivy - by Country
  • 12.6.2 Chart - Polivy Growth
• 12.7 Other Product
  • 12.7.1 Table Other Product - by Country
  • 12.7.2 Chart - Other Product Growth

13 ADC Therapeutic Markets - By User

• 13.1 Clinical
  • 13.1.1 Table Clinical - by Country
  • 13.1.2 Chart - Clinical Growth
• 13.2 Trial
  • 13.2.1 Table Trial - by Country
  • 13.2.2 Chart - Trial Growth
• 13.3 Research
  • 13.3.1 Table Research - by Country
  • 13.3.2 Chart - ResearchGrowth
• 13.4 Other User
  • 13.4.1 Table Other User - by Country
  • 13.4.2 Chart - Other User Growth

14 Appendices

• 14.1 FDA Cancer Drug Approvals by Year
• 14.2 Clinical Trials Started
• 14.3 Prevalence of Cancer Treatments

관련자료